315 related articles for article (PubMed ID: 34710876)
1. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
2. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
3. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
4. Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population.
Wu B; Muser E; Teeple A; Pericone CD; Feldman SR
J Dermatolog Treat; 2021 Sep; 32(6):595-602. PubMed ID: 31714168
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
6. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
7. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
[TBL] [Abstract][Full Text] [Related]
9. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
Sruamsiri R; Iwasaki K; Tang W; Mahlich J
BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Blauvelt A; Shi N; Burge R; Somani N; Ridenour TL; Zhu B; Atiya B; Lew CR; Zimmerman NM; Murage MJ
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
[TBL] [Abstract][Full Text] [Related]
12. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.
Goren A; Carter C; Lee S
J Dermatolog Treat; 2016; 27(1):43-50. PubMed ID: 26088404
[TBL] [Abstract][Full Text] [Related]
13. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
[TBL] [Abstract][Full Text] [Related]
14. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan.
Tada Y; Soliman AM; Ishii K; Sakuma R; Puig L; Davis M; Nunag D; Pinter A; Imafuku S
Dermatol Ther (Heidelb); 2024 Jan; 14(1):99-114. PubMed ID: 38019410
[TBL] [Abstract][Full Text] [Related]
15. Failure of Biologic Therapy in Psoriasis.
Cardona R; Pelet Del Toro NM; Michelen-Gómez E; Arias-Berrios GE; Martín-García RF
P R Health Sci J; 2021 Jun; 40(2):63-67. PubMed ID: 34543563
[TBL] [Abstract][Full Text] [Related]
16. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia.
Sullivan J; Hannam S; Puig A; Maranta D; McGeachie AB; Baker C
Australas J Dermatol; 2023 Nov; 64(4):504-513. PubMed ID: 37705180
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan.
Tada Y; Soliman AM; Ishii K; Sakuma R; Pinter A; Davis M; Nunag D; Buessing M; Puig L; Imafuku S
Exp Dermatol; 2024 May; 33(5):e15067. PubMed ID: 38757460
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
[TBL] [Abstract][Full Text] [Related]
20. Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
Ramos L; Ramos-Rodríguez J; Barreda R; Gutiérrez-Nicolás F; Carrillo-Palau M; Alonso-Abreu I; Nazco-Casariego J; Quintero E
Gastroenterol Hepatol; 2022 May; 45(5):335-341. PubMed ID: 34051312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
